NCT04981509 2026-03-18Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney CancerNational Cancer Institute (NCI)Phase 2 Recruiting65 enrolled
NCT04895748 2026-03-03DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other MalignanciesNovartisPhase 1 Terminated40 enrolled